BIOAGE LABS INC (BIOA)
Health Care · biotechnology · NASDAQ
A clinical-stage biotechnology company leveraging proprietary human aging datasets to develop therapies for metabolic and inflammation-driven diseases.
What BIOAGE LABS INC does
BioAge Labs is a clinical-stage biopharmaceutical company that identifies and develops therapeutic candidates for metabolic diseases by analyzing molecular data from human aging cohorts. Its pipeline is focused on targets identified through its proprietary platform, with lead programs including a brain-penetrant NLRP3 inhibitor and apelin receptor (APJ) agonists. The company is advancing these programs to address cardiometabolic conditions and ocular diseases.
Recent developments
In June 2026, BioAge dosed the first participant in its Phase 2 QUELL-CV trial for BGE-102, with topline data expected in the second half of 2026. The company also announced plans to initiate the QUELL-DME Phase 1b/2a trial in mid-2026.
From BIOAGE LABS INC's filing of 2026-08-05.
Themes: aging biology, metabolic disease, inflammation, NLRP3 inhibition, obesity, cardiovascular disease, ophthalmology
Fundamentals
- Price$5.56 as of 2026-10-20 close
- Market cap$255M as of 2026-07-31 (share count; price 2026-10-20)
- 1-year return+3.7% 2025-10-20 close $5.36 → 2026-10-20 close $5.56
- P/En/a negative earnings
- Net margin-896.1% FY2025, SEC XBRL
- ROE-29.6% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing reports debt under a line we do not read, so a total would be understated.
- Beta1.10 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How BIOA compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $2M | -$29M | -$26M | -$0.58 | -$19M† | $328000† |
| Q1 FY2026 2026-03-31 | $3M | -$25M | -$22M | -$0.52 | -$24M | $26000 |
| Q4 FY2025 2025-12-31 | $3M† | -$28M† | -$26M† | -$0.72† | -$28M† | $112000† |
| Q3 FY2025 2025-09-30 | $2M | -$23M | -$20M | -$0.56 | -$16M† | $22000† |
| Q2 FY2025 2025-06-30 | $2M | -$25M | -$22M | -$0.60 | -$20M† | $159000† |
| Q1 FY2025 2025-03-31 | $1M | -$16M | -$13M | -$0.36 | -$17M | $426000 |
| Q4 FY2024 2024-12-31 | — | -$25M† | -$21M† | $15.13† | -$5M† | $26000† |
| Q3 FY2024 2024-09-30 | $0 | -$25M | -$23M | -$6.70 | -$15M† | $305000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$74M
- Short-term investments$245M
- Total debtnot shown the filing reports its long-term debt in a form we do not read yet
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How BIOAGE LABS INC looks technically
BIOAGE LABS INC (BIOA) is trading 65.7% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 33 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 50, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 3 trading days ago. It is 78.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 65.7% below its 200-day average, the long-term trend line — a long-term downtrend | -65.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $8.18 | $8.18 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $16.20 | $16.20 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 28 calendar days ago — the swings before that are what the structure reading is measured on | 28 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes above 8.53. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 33 trading days ago — a "death cross", a bearish long-term signal | 33 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 50, with sellers in control | 49.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30) | 31.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($4.81 to $7.17) — its "stochastic" reading is 32 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 31.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $25.95 | $25.95 |
|---|---|---|
| From the 52-week high | it is 78.6% below its 52-week high (its highest price of the past year) | -78.6% |
| Above the 52-week low | it is 15.6% above its 52-week low (its lowest price of the past year) | +15.6% |
| Below the 52-week high | it is 78.6% below its highest point of the past year | 78.6% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $26.62 (set on 2024-10-22) | $26.62 |
| Given back of the 52-week move | over the past year its closes ranged ($4.84 to $25.10), and it has recovered only a small part of its fall from last year’s high — 4% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $17.36 to $18.01. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.5% |
| From the all-time high | it is 79.1% below its all-time high | -79.1% |
| Nearest price level | it is trading 8.8% above a support level at $5.07 — a price it turned at twice since 2025-08-29, most recently on 2025-10-17. Since 2024-10-21 it has 3 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -8.8% |
| All-time low | its lowest closing price on record is $2.88 (set on 2025-04-09) | $2.88 |
| Above the all-time low | it is 93.1% above its all-time low | +93.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 74% of it) | 74th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4689 between its high and its low — about 8.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4689 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.69 and $7.93 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.69 – $6.31 – $7.93 |
| Typical daily range (% of price) | its price moves about 8.4% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.4% |
| Stretch from the 200-day average | it is trading 22.7 daily ranges below its 200-day average price (65.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 22.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.44× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-20 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Open gap | it gapped 64.7% below the previous close 56 sessions ago and has not traded back through the level it left behind at 24.85 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -64.7% |
| Gap filled | a 2.3% gap down opened on 2026-09-01 has been "filled" 34 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 34 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +14.88% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 32.0 percentage points (the stock lost 31.0% while the market gained 1.0%) | -32.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 78.7 percentage points (the stock lost 75.1% while the market gained 3.6%) | -78.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 78.9 percentage points (the stock lost 70.4% while the market gained 8.5%) | -78.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 10.8 percentage points (the stock gained 3.7% while the market gained 14.6%) | -10.8% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 42% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 134.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -42.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 63% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $15.23 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | -63.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 31% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $8.09 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | -31.3% |
Price levels it has turned at before
BIOA last closed at $5.56 on 2026-10-20. Since 2024-10-21 it has turned at 3 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.07 | Support | 8.8% below the last close | turned there twice · 2025-08-29 to 2025-10-17 |
| $4.67 | Support | 16.0% below the last close | turned there four times · 2025-03-03 to 2025-09-16 |
| $4.09 | Support | 26.5% below the last close | turned there four times · 2025-02-25 to 2025-08-01 |
| $8.56 | Resistance | 54.0% above the last close | turned there four times · 2025-10-23 to 2026-09-22 |
| $11.90 | Resistance | 114.1% above the last close | turned there twice · 2026-01-05 to 2026-08-07 |
| $17.93 | Resistance | 222.5% above the last close | turned there twice · 2024-11-18 to 2026-06-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes above $8.53.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $4.03 and $6.81 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 16 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · MACD just crossed bullish (12/26/9) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.80 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$32.56 range $8.00 – $73.00; median $25.00
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BIOA
- Consensus EPS estimate-$0.6261 next reporting period, as of 2026-10-20
- Estimate change, 30 days-$0.01855 from -$0.6076, on 2026-09-15, 35-day window
- Readings revised upward0% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is clinical-stage with no commercial products and has a history of significant operating losses.","The company is subject to potential litigation risks and costs, including past securities class action complaints."]
What changed in the latest 10-Q
AI-assisted comparison of BIOA's 10-Q filed 2026-08-05 against the prior one filed 2026-05-08.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (filed 2026-08-05) adds a new paragraph stating that based on the aggregate market value of common stock held by non-affiliates as of June 30, 2026, which exceeded $700.0 million, the company expects to cease being an emerging growth company and a smaller reporting company as of December 31, 2026.
- Newer filing (filed 2026-08-05) adds that beginning with the Quarterly Report on Form 10-Q for the quarter ending March 31, 2027, the company expects to become subject to requirements applicable to non-accelerated filers that are neither emerging growth companies nor smaller reporting companies, including expanded executive compensation and financial statement disclosure.
- Newer filing (filed 2026-08-05) adds that the company will no longer be able to rely on the extended transition period under Section 107(b) of the JOBS Act and will be required to adopt new or revised accounting standards as of the effective dates applicable to public companies that are not emerging growth companies.
- Removed:
- Older filing (filed 2026-05-08) contains a paragraph under the Risk Factors section titled "Risk Factors Summary" with a bulleted list of risks beginning with "We are a clinical-stage biopharmaceutical company with a limited operating history...", which is not present in the newer filing (filed 2026-08-05).
- Older filing (filed 2026-05-08) contains a sentence stating that the United States Court of Appeals for the Ninth Circuit has set the deadline for the plaintiff's opening brief for June 22, 2026, which is replaced by updated information in the newer filing.
- Reworded:
- The newer filing (filed 2026-08-05) states the review of critical accounting policies and estimates was for the "six months ended June 30, 2026," while the older filing (filed 2026-05-08) states it was for the "three months ended March 31, 2026."
- The newer filing (filed 2026-08-05) states that disclosure controls and procedures were effective as of "June 30, 2026," while the older filing (filed 2026-05-08) states they were effective as of "March 31, 2026."
- The newer filing (filed 2026-08-05) states that the evaluation of internal control over financial reporting covered the quarter ended "June 30, 2026," while the older filing (filed 2026-05-08) states it covered the quarter ended "March 31, 2026."
- In the Legal Proceedings section, the older filing (filed 2026-05-08) describes the complaint as alleging misrepresentations and/or omissions in the company's "Registration Statement concerning azelaprag," while the newer filing (filed 2026-08-05) describes it as alleging misrepresentations and/or omissions in the company's "initial public offering registration statement concerning azelaprag."
- In the Legal Proceedings section, the newer filing (filed 2026-08-05) adds updates regarding the appeal: the plaintiff filed its opening brief on July 22, 2026; defendants' answering brief is due on September 18, 2026; any reply brief is due by October 2, 2026; and oral argument would likely occur in early 2027.
- The newer filing (filed 2026-08-05) is truncated at the end of the Risk Factors section, with text ending mid-sentence at "These disclosures reflect the Company's beliefs and opinions as to factors that could materially and adver," while the older filing (filed 2026-05-08) contains the complete sentence and subsequent content including the Risk Factors Summary section.
- Notes:
- The newer filing text is truncated mid-sentence at the end of the provided excerpt, so the full Risk Factors section in the newer filing could not be compared beyond the point of truncation.
- The comparison covers only the provided excerpts of the MD&A sections and does not include other portions of the filings.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 180 days · read to 2026-10-160 buys · 2 sells ($2M) — 1 selling insider
Most recent open-market transaction: 2026-06-30. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BIOA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding BIOA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 4,496,934
- Reported value $110,219,852
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about BIOA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
BIOA had 3,274,379 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
BIOA had 7.13% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.94 days to cover at the same settlement.
- Reported short interest (shares) 3,274,379
- Short interest (% of shares outstanding) 7.13%
- Prior settlement (shares) 3,073,976
- Reported change 6.52%
- Days to cover (reported) 3.94
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Eli Lilly (LLY)
- Novartis (NVS)
- Regeneron Pharmaceuticals (REGN)
- Roche (RHHBY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BIOA vs…
BIOAGE LABS INC is found in…
Frequently asked questions
What does BIOAGE LABS INC (BIOA) do?
BioAge Labs is a clinical-stage biopharmaceutical company that identifies and develops therapeutic candidates for metabolic diseases by analyzing molecular data from human aging cohorts. Its pipeline is focused on targets identified through its proprietary platform, with lead programs including a brain-penetrant NLRP3 inhibitor and apelin receptor (APJ) agonists. The company is advancing these programs to address cardiometabolic conditions and ocular diseases.
What sector is BIOAGE LABS INC (BIOA) in?
BIOAGE LABS INC (BIOA) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are BIOAGE LABS INC's (BIOA) competitors?
Notable peers of BIOAGE LABS INC (BIOA) include Eli Lilly, Novartis, Regeneron Pharmaceuticals and Roche. This peer set is informational only — not financial advice.
Is BIOAGE LABS INC (BIOA) overbought or oversold right now?
BIOAGE LABS INC (BIOA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 32, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BIOA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.